Literature DB >> 20920845

A simplified method to assess affinity of insulin autoantibodies.

Peter Achenbach1, Liang-Hao Guo, Claudia Gick, Kerstin Adler, Stephanie Krause, Ezio Bonifacio, Peter G Colman, Anette-G Ziegler.   

Abstract

Insulin autoantibodies (IAA) precede type 1 diabetes, but not all IAA-positive children develop other islet autoantibodies and disease. Diabetes risk can be stratified by laborious IAA affinity measurement using competition with multiple ligand concentrations. Here, we identify a single competitor concentration that discriminates low- and high-affinity IAA. Discrimination was achieved among 122 IAA-positive sera using 7.0 nM competitor which is 54-fold that of the assay radioligand concentration. Relative-binding <60% at this competitor concentration identified all 85 sera with affinities ≥1.0×10⁸ L/mol and none with lower affinities (P<0.0001), and 45 (96%) of 47 multiple islet autoantibody-positive sera (P<0.0001). IAA competition was further tested in a second set of 119 IAA-positive sera. Of these, 99 fulfilled high-affinity competition criteria of <60% relative-binding at 7.0 nM competitor including 89 (94%) of 95 sera with multiple islet autoantibodies (P<0.0001). Thus, increased IAA specificity can be achieved with simple modification to existing assays.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920845     DOI: 10.1016/j.clim.2010.09.002

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

1.  'Insulin autoantibody affinity measurement using a single concentration of unlabelled insulin competitor discriminates risk in relatives of patients with type 1 diabetes.

Authors:  R M Curnock; C R Reed; S Rokni; J W Broadhurst; P J Bingley; A J K Williams
Journal:  Clin Exp Immunol       Date:  2012-01       Impact factor: 4.330

2.  Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 Diabetes.

Authors:  Alistair J K Williams; Vito Lampasona; Michael Schlosser; Patricia W Mueller; David L Pittman; William E Winter; Beena Akolkar; Rebecca Wyatt; Cristina Brigatti; Stephanie Krause; Peter Achenbach
Journal:  Diabetes       Date:  2015-05-13       Impact factor: 9.461

Review 3.  Birth and coming of age of islet autoantibodies.

Authors:  E Bonifacio; P Achenbach
Journal:  Clin Exp Immunol       Date:  2019-09-12       Impact factor: 4.330

Review 4.  Biomarkers: Tools for Discriminating MODY from Other Diabetic Subtypes.

Authors:  Parveena Firdous; Kamran Nissar; Shariq Rashid Masoodi; Bashir Ahmad Ganai
Journal:  Indian J Endocrinol Metab       Date:  2022-08-04

5.  Assessment and Management of Anti-Insulin Autoantibodies in Varying Presentations of Insulin Autoimmune Syndrome.

Authors:  David Church; Luís Cardoso; Richard G Kay; Claire L Williams; Bernard Freudenthal; Catriona Clarke; Julie Harris; Myuri Moorthy; Efthmia Karra; Fiona M Gribble; Frank Reimann; Keith Burling; Alistair J K Williams; Alia Munir; T Hugh Jones; Dagmar Führer; Lars C Moeller; Mark Cohen; Bernard Khoo; David Halsall; Robert K Semple
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.